ストックスクリーナーアプリを入手
0.012
5.75%
0.00065
前日終値:
$0.0113
開ける：
$0.01
24時間の取引高:
541.69K
Relative Volume:
9.32
時価総額：
$N/A
収益：
-
当期純損益:
$-20.70M
株価収益率:
-0.000163
EPS:
-73.3042
ネットキャッシュフロー:
$-14.40M
1週間 パフォーマンス:
-19.80%
1か月 パフォーマンス:
+12.74%
6か月 パフォーマンス:
-99.97%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.01
$0.0125
1週間の範囲:
$0.01
$0.0126
52週間の値動き範囲:
$0.01
$0.0149
Cero Therapeutics Holdings Inc Stock (CERO) Company Profile
Compare CERO vs VRTX, REGN, MRNA, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CERO
Cero Therapeutics Holdings Inc
|
0.012 | 0 | 0 | -20.70M | -14.40M | -73.30 |
VRTX
Vertex Pharmaceuticals Inc
|
514.99 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.90 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.56 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
963.79 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
368.08 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cero Therapeutics Holdings Inc Stock (CERO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-23 | アップグレード | D. Boral Capital | Hold → Buy |
Cero Therapeutics Holdings Inc (CERO) 最新ニュース
BTAIQ Stock Price and Chart — OTC:BTAIQ - TradingView
SRx Health Solutions Secures Major CERo Financing Deal - TipRanks
SRX Global (SRXH) lines up $11.7M for CERo, backed by its cell therapy assets - Stock Titan
CERo Therapeutics Holdings Secures New Consolidated Financing Facility - TipRanks
CERo Therapeutics (CERO) folds $5.7M debt into 10% secured note due Oct 2026 - Stock Titan
CERo Therapeutics Secures Up to $11.67 Million SRX Financing, Consolidates $5.67 Million Debt - TradingView
BCAB Stock Price and Chart — OTC:BCAB - TradingView
SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers - Yahoo Finance
CERo Therapeutics Holdings, Inc. announced that it has received $6 million in funding from SRx Health Solutions Inc. - marketscreener.com
Price to earnings forward of CERo Therapeutics Holdings, Inc. – OTC:CEROW - TradingView
CERo Therapeutics (CERO) warns on going concern as losses mount and deficit widens - Stock Titan
CERo Therapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Cero Therapeutics (CERO) holder Isaiah Tibbs reports 4.63% ownership stake - Stock Titan
CERo Therapeutics Holdings, Inc. Revenue Breakdown – OTC:CERO - TradingView
CERo Therapeutics Holdings, Inc. Revenue Breakdown – OTC:CEROW - TradingView
CERo Therapeutics Expands Convertible Debt Financing Arrangement - TipRanks
CERO Therapeutics (OTCQB: CERO) details $2,606,500 discounted convertible note funding - Stock Titan
Cero Therapeutics Secures $2.09M 10% Convertible Note With SRX Global, Maturing May 2027 - TradingView
CERO Therapeutics (CERO) details $2,085,200 10% convertible note deal - Stock Titan
BNBX Stock Price and Chart — OTC:BNBX - TradingView
CERo Therapeutics Holdings, Inc. announced that it has received $2.0852 million in funding from SRx Health Solutions Inc. - marketscreener.com
[25-NSE] CERO THERAPEUTICS HOLDINGS, INC. SEC Filing - Stock Titan
Delisting of Securities from The Nasdaq Stock Market - The Manila Times
Nasdaq to delist multiple suspended stocks incl... - Pluang
Price to earnings forward of CERo Therapeutics Holdings, Inc. – OTC:CERO - TradingView
Price to sales forward of CERo Therapeutics Holdings, Inc. – OTC:CERO - TradingView
Enterprise value to EBITDA forward of CERo Therapeutics Holdings, Inc. – OTC:CERO - TradingView
CERo Therapeutics Amends Convertible Note, Expands Private Financing - TipRanks
CERO Therapeutics (OTCQB: CERO) registers 729.6M shares; files convertible note details - Stock Titan
CERO Therapeutics (CERO) inks $1.41M 10% convertible note with stock conversion - Stock Titan
CERo Therapeutics Holdings, Inc. Actuals & Estimates (OTC:CERO) - TradingView
ADTX Stock Price and Chart — OTC:ADTX - TradingView
CERo Therapeutics Holdings Inc (CERO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CERo Therapeutics Holdings, Inc. announced that it has received $1.4136 million in funding from SRx Health Solutions Inc. - marketscreener.com
CERo Therapeutics Holdings Inc (CEROW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CERo Therapeutics Holdings Inc (CERO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CERo Therapeutics Holdings Inc - TradingKey
CERo Therapeutics Holdings Inc (CERO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CERo Therapeutics Holdings Inc (CERO) Institutional Confidence - TradingKey
CERo Therapeutics Holdings Inc (CERO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CERo Therapeutics Holdings Inc (CERO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CERo Therapeutics Holdings Inc (CERO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CERo Therapeutics Holdings Inc (CERO) Valuation: PE, PB & Fair Value Analysis - TradingKey
CERo Therapeutics Holdings Inc (CEROW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CERo Therapeutics Holdings Inc (CEROW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CERo Therapeutics Holdings Inc (CEROW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CERo Therapeutics Holdings Inc (CEROW) Valuation: PE, PB & Fair Value Analysis - TradingKey
CERo Therapeutics Holdings Inc (CEROW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CERo Therapeutics Holdings Inc (CEROW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CERo Therapeutics Holdings Inc (CEROW) Institutional Confidence - TradingKey
CERo Therapeutics Holdings Announces Clinical Update From CERTAIN-T Phase 1 CER-1236 Trial - marketscreener.com
Cero Therapeutics Holdings Inc (CERO) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.15%
大文字化:
|
ボリューム (24 時間):